Based on the randomized, phase III BEACON trial, a combination of encorafenib and binimetinib (a MEK inhibitor) with cetuximab has been recommended as a second-line systemic therapy for BRAF V600E mutation CRC. Here, MAP2K7 is linked to colorectal carcinoma.